{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T09:22:20Z","timestamp":1778318540245,"version":"3.51.4"},"reference-count":70,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Lung cancer continues to be a significant burden worldwide and remains the leading cause of cancer-associated mortality. Two considerable challenges posed by this disease are the diagnosis of 61% of patients in advanced stages and the reduced five-year survival rate of around 4%. Noninvasively collected samples are gaining significant interest as new areas of knowledge are being sought and opened up. Metabolomics is one of these growing areas. In recent years, the use of metabolomics as a resource for the study of lung cancer has been growing. We conducted a systematic review of the literature from the past 10 years in order to identify some metabolites associated with lung cancer. More than 150 metabolites have been associated with lung cancer-altered metabolism. These were detected in different biological samples by different metabolomic analytical platforms. Some of the published results have been consistent, showing the presence\/alteration of specific metabolites. However, there is a clear variability due to lack of a full clinical characterization of patients or standardized patients selection. In addition, few published studies have focused on the added value of the metabolomic profile as a means of predicting treatment response for lung cancer. This review reinforces the need for consistent and systematized studies, which will help make it possible to identify metabolic biomarkers and metabolic pathways responsible for the mechanisms that promote tumor progression, relapse and eventually resistance to therapy.<\/jats:p>","DOI":"10.3390\/metabo11090630","type":"journal-article","created":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T00:13:47Z","timestamp":1631924027000},"page":"630","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Metabolomic Profiling in Lung Cancer: A Systematic Review"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6828-6477","authenticated-orcid":false,"given":"Daniela","family":"Madama","sequence":"first","affiliation":[{"name":"Clinical Academic Center of Coimbra (CACC), Department of Pulmonology, Faculty of Medicine, University Hospitals of Coimbra, University of Coimbra, 3004-504 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1679-0935","authenticated-orcid":false,"given":"Rosana","family":"Martins","sequence":"additional","affiliation":[{"name":"Coimbra Institute for Clinical and Biomedical Research (iCBR), Biophysics Institute of Faculty of Medicine of University of Coimbra, Area of Environmental Genetics and Oncobiology (CIMAGO), 3000-548 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7994-4650","authenticated-orcid":false,"given":"Ana S.","family":"Pires","sequence":"additional","affiliation":[{"name":"Clinical Academic Center of Coimbra (CACC), Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra Institute for Clinical and Biomedical Research (iCBR), Biophysics Institute of Faculty of Medicine of University of Coimbra, Area of Environmental Genetics and Oncobiology (CIMAGO), 3000-548 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7202-1650","authenticated-orcid":false,"given":"Maria F.","family":"Botelho","sequence":"additional","affiliation":[{"name":"Clinical Academic Center of Coimbra (CACC), Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra Institute for Clinical and Biomedical Research (iCBR), Biophysics Institute of Faculty of Medicine of University of Coimbra, Area of Environmental Genetics and Oncobiology (CIMAGO), 3000-548 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7635-783X","authenticated-orcid":false,"given":"Marco G.","family":"Alves","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Unit for Multidisciplinary Research in Biomedicine (UMIB), Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4099-002 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4185-7871","authenticated-orcid":false,"given":"Ana M.","family":"Abrantes","sequence":"additional","affiliation":[{"name":"Clinical Academic Center of Coimbra (CACC), Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra Institute for Clinical and Biomedical Research (iCBR), Biophysics Institute of Faculty of Medicine of University of Coimbra, Area of Environmental Genetics and Oncobiology (CIMAGO), 3000-548 Coimbra, Portugal"}]},{"given":"Carlos R.","family":"Cordeiro","sequence":"additional","affiliation":[{"name":"Clinical Academic Center of Coimbra (CACC), Department of Pulmonology, Faculty of Medicine, University Hospitals of Coimbra, University of Coimbra, 3004-504 Coimbra, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/1055-9965.EPI-15-1191","article-title":"Urinary Metabolite Risk Biomarkers of Lung Cancer: A Prospective Cohort Study","volume":"25","author":"Haznadar","year":"2016","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.arbr.2017.10.014","article-title":"New Immunotherapy and Lung Cancer","volume":"53","year":"2017","journal-title":"Arch. Bronconeumol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/1753465817725486","article-title":"Pembrolizumab in the treatment of metastatic non-small cell lung cancer: A review of current evidence","volume":"11","author":"Rihawi","year":"2017","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3390\/metabo5020192","article-title":"Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry","volume":"5","author":"Miyamoto","year":"2015","journal-title":"Metabolites"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation","volume":"324","author":"Cantley","year":"2009","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"ref_9","unstructured":"Wells, G.A., Shea, B., O\u2019Connell, D., Peterson, J., Welch, V., Losos, M., and Tugwell, P. (2021, March 17). The Newcastle-Ottawa Scale for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available online: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100907","DOI":"10.1016\/j.tranon.2020.100907","article-title":"Early lung cancer diagnostic biomarker discovery by machine learning","volume":"14","author":"Xie","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jtho.2015.09.002","article-title":"Metabolite Profiles of the Serum of Patients with Non\u2013Small Cell Carcinoma","volume":"11","author":"Mazzone","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"207ra142","DOI":"10.1126\/scitranslmed.3007013","article-title":"A Blood-Based Proteomic Classifier for the Molecular Characterization of Pulmonary Nodules","volume":"5","author":"Li","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1158\/1055-9965.EPI-13-0770","article-title":"Circulating Biomarkers of Tryptophan and the Kynurenine Pathway and Lung Cancer Risk","volume":"23","author":"Chuang","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"12904","DOI":"10.18632\/oncotarget.7354","article-title":"Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer","volume":"7","author":"Lewintre","year":"2016","journal-title":"Oncotarget"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00432-017-2347-0","article-title":"Study of early stage non-small-cell lung cancer using Orbitrap-based global serum metabolomics","volume":"143","author":"Klupczynska","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Zhang, L., Zheng, J., Ahmed, R., Huang, G., Reid, J., Mandal, R., Maksymuik, A., Sitar, D.S., Tappia, P.S., and Ramjiawan, B. (2020). A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection. Cancers, 12.","DOI":"10.3390\/cancers12030622"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Miyagi, Y., Higashiyama, M., Gochi, A., Akaike, M., Ishikawa, T., Miura, T., Saruki, N., Bando, E., Kimura, H., and Imamura, F. (2011). Plasma Free Amino Acid Profiling of Five Types of Cancer Patients and Its Application for Early Detection. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024143"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"19356","DOI":"10.18632\/oncotarget.25049","article-title":"Circulating and tumor-associated caspase-4: A novel diagnostic and prognostic biomarker for non-small cell lung cancer","volume":"9","author":"Terlizzi","year":"2018","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Shingyoji, M., Iizasa, T., Higashiyama, M., Imamura, F., Saruki, N., Imaizumi, A., Yamamoto, H., Daimon, T., Tochikubo, O., and Mitsushima, T. (2013). The significance and robustness of a plasma free amino acid (PFAA) profile-based multiplex function for detecting lung cancer. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-77"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"107899","DOI":"10.18632\/oncotarget.22391","article-title":"Global lipidomics identified plasma lipids as novel biomarkers for early detection of lung cancer","volume":"8","author":"Yu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1158\/1055-9965.EPI-14-0007","article-title":"Prospective Population-Based Study of the Association between Serum 25-Hydroxyvitamin-D Levels and the Incidence of Specific Types of Cancer","volume":"23","author":"Skaaby","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/bmc.3755","article-title":"Simultaneous determination of thirteen kinds of amino acid and eight kinds of acylcarnitine in human serum by LC-MS\/MS and its application to measure the serum concentration of lung cancer patients","volume":"30","author":"Ni","year":"2016","journal-title":"Biomed. Chromatogr."},{"key":"ref_23","first-page":"188","article-title":"Targeted metabolomics for serum amino acids and acylcarnitines in patients with lung cancer","volume":"18","author":"Ni","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/ije\/dyy100","article-title":"Circulating cotinine concentrations and lung cancer risk in the Lung Cancer Cohort Consortium (LC3)","volume":"47","author":"LaRose","year":"2018","journal-title":"Int. J. Epidemiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40170-019-0195-x","article-title":"Stratification of cancer and diabetes based on circulating levels of formate and glucose","volume":"7","author":"Pietzke","year":"2019","journal-title":"Cancer Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10238-019-00566-7","article-title":"Serum lipidome screening in patients with stage I non-small cell lung cancer","volume":"19","author":"Klupczynska","year":"2019","journal-title":"Clin. Exp. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"11981","DOI":"10.1002\/jcb.28482","article-title":"Integration of metabolomic and transcriptomic profiles to identify biomarkers in serum of lung cancer","volume":"120","author":"Sun","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1158\/1055-9965.EPI-15-0427","article-title":"Investigation of Metabolomic Blood Biomarkers for Detection of Adenocarcinoma Lung Cancer","volume":"24","author":"Fahrmann","year":"2015","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Singhal, S., Rolfo, C., Maksymiuk, A.W., Tappia, P.S., Sitar, D.S., Russo, A., Akhtar, P.S., Khatun, N., Rahnuma, P., and Rashiduzzaman, A. (2019). Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study. Cancers, 11.","DOI":"10.3390\/cancers11081069"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3233\/CBM-150506","article-title":"Plasma 25-hydroxyvitamin D deficiency is associated with the risk of non-small cell lung cancer in a Chinese population","volume":"15","author":"Wang","year":"2015","journal-title":"Cancer Biomark."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jnci\/djx119","article-title":"Circulating Folate, Vitamin B6, and Methionine in Relation to Lung Cancer Risk in the Lung Cancer Cohort Consortium (LC3)","volume":"110","author":"Fanidi","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2017.07.036","article-title":"Serum lipid profile discriminates patients with early lung cancer from healthy controls","volume":"112","author":"Jelonek","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.lungcan.2017.10.018","article-title":"Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy","volume":"114","author":"Maosheng","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1158\/1078-0432.CCR-17-2855","article-title":"Prediction of Chemotherapeutic Efficacy in Non\u2013Small Cell Lung Cancer by Serum Metabolomic Profiling","volume":"24","author":"Tian","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Hao, D., Sengupta, A., Ding, K., Ubeydullah, E., Krishnaiah, S., Leighl, N.B., Shepherd, F.A., Seymour, L., and Weljie, A. (2020). Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy. Cancers, 12.","DOI":"10.3390\/cancers12071926"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11306-016-0961-5","article-title":"Temporal characterization of serum metabolite signatures in lung cancer patients undergoing treatment","volume":"12","author":"Hao","year":"2016","journal-title":"Metabolomics"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ghini, V., Laera, L., Fantechi, B., Del Monte, F., Benelli, M., McCartney, A., Leonardo, T., Luchinat, C., and Pozzessere, D. (2020). Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer. Cancers, 12.","DOI":"10.3390\/cancers12123574"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1615\/CritRevBiomedEng.2013007736","article-title":"Metabolomic Fingerprinting: Challenges and Opportunities","volume":"41","author":"Kosmides","year":"2013","journal-title":"Crit. Rev. Biomed. Eng."},{"key":"ref_39","unstructured":"Matthiesen, R. (2010). Computational approaches to metabolomics. Bioinformatics Methods in Clinical Research Methods in Molecular Biology, Humana Press."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Stevens, V.L., Hoover, E., Wang, Y., and Zanetti, K.A. (2019). Pre-Analytical Factors that Affect Metabolite Stability in Human Urine, Plasma, and Serum: A Review. Metabolites, 9.","DOI":"10.3390\/metabo9080156"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3389\/fimmu.2016.00044","article-title":"Metabolomics and Its Application to Acute Lung Diseases","volume":"7","author":"Stringer","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.molmet.2019.08.010","article-title":"Clinical and lifestyle related factors influencing whole blood metabolite levels\u2014A comparative analysis of three large cohorts","volume":"29","author":"Beuchel","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3945\/ajcn.116.135301","article-title":"Comparing metabolite profiles of habitual diet in serum and urine","volume":"104","author":"Playdon","year":"2016","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s11306-012-0452-2","article-title":"Metabolomic profiling of lung and prostate tumor tissues by capillary electrophoresis time-of-flight mass spectrometry","volume":"9","author":"Kami","year":"2012","journal-title":"Metabolomics"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Lee, K.B., Ang, L., Yau, W.-P., and Seow, W.J. (2020). Association between Metabolites and the Risk of Lung Cancer: A Systematic Literature Review and Meta-Analysis of Observational Studies. Metabolites, 10.","DOI":"10.3390\/metabo10090362"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.18632\/oncotarget.6467","article-title":"Understanding the role of the kynurenine pathway in human breast cancer immunobiology","volume":"7","author":"Heng","year":"2015","journal-title":"Oncotarget"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1089\/ars.2017.7350","article-title":"Proline Metabolism in Cell Regulation and Cancer Biology: Recent Advances and Hypotheses","volume":"30","author":"Phang","year":"2019","journal-title":"Antioxid. Redox Signal."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"15267","DOI":"10.1038\/ncomms15267","article-title":"Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells","volume":"8","author":"Elia","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"17206","DOI":"10.1038\/srep17206","article-title":"Proline biosynthesis augments tumor cell growth and aerobic glycolysis: Involvement of pyridine nucleotides","volume":"5","author":"Liu","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cmet.2016.08.008","article-title":"Proline Starvation Induces Unresolved ER Stress and Hinders mTORC1-Dependent Tumorigenesis","volume":"24","author":"Sahu","year":"2016","journal-title":"Cell Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-46643-5","article-title":"Magnetic Resonance Spectroscopy-based Metabolomic Biomarkers for Typing, Staging, and Survival Estimation of Early-Stage Human Lung Cancer","volume":"9","author":"Berker","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/rcm.6656","article-title":"Liquid chromatography\/mass spectrometry methods for measuring dipeptide abundance in non-small-cell lung cancer","volume":"27","author":"Wu","year":"2013","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.18632\/oncotarget.27724","article-title":"Altered lung tissue lipidomic profile in caspase-4 positive nonsmall cell lung cancer (NSCLC) patients","volume":"11","author":"Terlizzi","year":"2020","journal-title":"Oncotarget"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1158\/1940-6207.CAPR-14-0329","article-title":"Metabolomic Markers of Altered Nucleotide Metabolism in Early Stage Adenocarcinoma","volume":"8","author":"Wikoff","year":"2015","journal-title":"Cancer Prev. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s13238-014-0082-8","article-title":"Regulation of the pentose phosphate pathway in cancer","volume":"5","author":"Jiang","year":"2014","journal-title":"Protein Cell"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Benowitz, N.L., Hukkanen, J., and Jacob, P. (2009). Nicotine Chemistry, Metabolism, Kinetics and Biomarkers. Handbook of Experimental Pharmacology, Springer.","DOI":"10.1007\/978-3-540-69248-5_2"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"6749","DOI":"10.1158\/0008-5472.CAN-11-0209","article-title":"Urinary Levels of Cigarette Smoke Constituent Metabolites Are Prospectively Associated with Lung Cancer Development in Smokers","volume":"71","author":"Yuan","year":"2011","journal-title":"Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/carcin\/bgs026","article-title":"Urinary levels of volatile organic carcinogen and toxicant biomarkers in relation to lung cancer development in smokers","volume":"33","author":"Yuan","year":"2012","journal-title":"Carcinogenesis"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/carcin\/bgx012","article-title":"CYP2A6 genetic polymorphisms and biomarkers of tobacco smoke constituents in relation to risk of lung cancer in the Singapore Chinese Health Study","volume":"38","author":"Yuan","year":"2017","journal-title":"Carcinogenesis"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/carcin\/bgt352","article-title":"Urinary metabolites of a polycyclic aromatic hydrocarbon and volatile organic compounds in relation to lung cancer development in lifelong never smokers in the Shanghai Cohort Study","volume":"35","author":"Yuan","year":"2014","journal-title":"Carcinogenesis"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.7314\/APJCP.2013.14.11.6591","article-title":"Levels of Tobacco-specific Metabolites among Non-smoking Lung Cancer Cases at Diagnosis: Case-control Findings","volume":"14","author":"Hwang","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s13105-016-0465-9","article-title":"Tobacco nitrosamines as culprits in disease: Mechanisms reviewed","volume":"72","author":"Yalcin","year":"2016","journal-title":"J. Physiol. Biochem."},{"key":"ref_63","first-page":"1501","article-title":"r-1,t-2,3,c-4-Tetrahydroxy-1,2,3,4-tetrahydrophenanthrene in human urine: A potential biomarker for assessing polycyclic aromatic hydrocarbon metabolic activation","volume":"12","author":"Hecht","year":"2003","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jpba.2018.09.055","article-title":"Metabolomic study of serum, urine and bronchoalveolar lavage fluid based on gas chromatography mass spectrometry to delve into the pathology of lung cancer","volume":"163","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/carcin\/bgu226","article-title":"NMR metabolomics of human lung tumors reveals distinct metabolic signatures for adenocarcinoma and squamous cell carcinoma","volume":"36","author":"Rocha","year":"2015","journal-title":"Carcinogenesis"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3945\/ajcn.114.096099","article-title":"Serum biomarkers of habitual coffee consumption may provide insight into the mechanism underlying the association between coffee consumption and colorectal cancer","volume":"101","author":"Guertin","year":"2015","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_67","first-page":"482","article-title":"Association of tumor differentiation with caffeine and coffee intake in women with breast cancer","volume":"100","author":"Pozner","year":"1986","journal-title":"Surgery"},{"key":"ref_68","first-page":"4375","article-title":"Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine","volume":"59","author":"Sarkaria","year":"1999","journal-title":"Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"S2090","DOI":"10.1016\/j.jtho.2017.09.1157","article-title":"P2.01-055 Examining Metabolomics as a Prognostic Marker in Metastatic Non\u2013Small Cell Lung Cancer Patients Undergoing First-Line Chemotherapy","volume":"12","author":"Hao","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/1878-0261.12369","article-title":"Metabolomic profiling of human lung tumor tissues\u2014nucleotide metabolism as a candidate for therapeutic interventions and biomarkers","volume":"12","author":"Moreno","year":"2018","journal-title":"Mol. Oncol."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/11\/9\/630\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:01:18Z","timestamp":1760166078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/11\/9\/630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":70,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["metabo11090630"],"URL":"https:\/\/doi.org\/10.3390\/metabo11090630","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,17]]}}}